Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Renal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Renal Cancer
    TopAbstracts in Renal Cancer 11/25/2009 - (DGNews)
    Recipient, Donor Race May Affect Mortality in Kidney Transplantation - (DGNews)
    TopAbstracts in Renal Cancer 11/11/2009 - (DGNews)
    TopAbstracts in Renal Cancer 10/28/2009 - (DGNews)
    FDA Approves Pazopanib for Advanced Renal Cell Carcinoma - (DGNews)

    News archive

     Recent webcasts/CME - Renal Cancer

    Webcasts/CME archive

     Recent cases - Renal Cancer
      Synchronous Lingual and Thyroid Metastasis from Renal Cell Carcinoma
      Granulocytosis and Thrombocytosis in Renal Cell Carcinoma: A Pro-Inflammatory Cytokine Response Originating in the Tumour
      Xp11.2 Translocation Renal Cell Carcinoma Occurring During Pregnancy with a Novel Translocation Involving Chromosome 19: A Case Report with Review of the Literature
      Stauffer's Syndrome as a Prominent Manifestation of Renal Cancer: A Case Report
      Oral Cavity Metastasis of Renal Cell Carcinoma: A Case Report

      Cases archive
        




      my personal edition > renal cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Sorafenib (Nexavar) Improves Survival in Elderly Renal-Cancer Patients: Presented at ESMO

      By Jill Stein

      ISTANBUL, TURKEY -- September 30, 2006 -- The survival improvement in older patients with advanced renal-cell carcinoma who are treated with sorafenib (Nexavar) rivals that observed in younger patients, according to results presented here at the 31st European Society for Medical Oncology (ESMO) Scientific and Educational Congress.

      Tim Eisen, MD, senior lecturer, medical oncology division, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom, and colleagues assessed the effect of age on clinical outcomes and tolerability with sorafenib treatment.

      "While the incidence of renal-cell carcinoma increases dramatically with age, older patients are often under-represented in oncology trials and inherently perceived [as being] at higher risk of toxicity with less than optimal outcomes," Dr. Eisen pointed out in his presentation on September 30th.

      The analysis used data from a phase 3 trial of sorafenib that enrolled 903 patients. Of 451 sorafenib-treated patients, 305 were less than 65 years of age, and 146 patients were 65 years of age or older. No differences were noted in baseline demographics or co-morbidities for sorafenib-treated patients across age subgroups versus placebo.

      Clinical benefit was observed in about 85% of patients receiving sorafenib in the subgroups under 65 years of age and 65 years of age or older.

      Sorafenib consistently resulted in a 2-fold improvement in median progression-free survival (PFS) versus placebo. Regardless of age, PFS benefit with sorafenib was consistent by patient subgroups.

      No difference was observed in adverse-effect profiles of sorafenib by age.

      By the fifth cycle, most of the sorafenib-treated patients reported "stable" or "better" symptom response than placebo.

      At weeks 18 and 24, more sorafenib-treated patients had stable or improved total scores in Functional Assessment of Cancer Therapy-Kidney Symptom Index from baseline compared with placebo.

      Overall, the results show that sorafenib demonstrated similar clinical benefit and a low toxicity profile irrespective of age, Dr. Eisen noted.

      The study was sponsored by Bayer Pharmaceuticals.


      [Presentation title: Clinical Benefit of Sorafenib in the Elderly With Advanced Renal Cell Carcinoma: Subgroup Analysis of the Approaches in Renal Cancer Global Evaluation Trial (TARGETS). Abstract Number 446PD]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send